Edwards Lifesciences Disagrees With FTC Block on JenaValve But Gets Back To Business

Long-Term Aortic Regurgitation Portfolio Assumptions Come Under Scrutiny.

 
• By Shubham Singh
  
IRVINE, CALIFORNIA - 7 MAY 2023: Edwards Lifesciences is a global leader in medical innovations for structural heart disease, critical care and surgical monitoring.
Edwards said it remains committed to advancing treatment options for AR patients and will continue development of its SOJOURN transcatheter valve while enrolling patients in the JOURNEY pivotal trial. (Shutterstock)

More from Deals

More from Business